Welcome to our dedicated page for TriSalus Life Sciences SEC filings (Ticker: TLSI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
TriSalus Life Sciences, Inc. filings document operating results, governance actions and capital-structure matters for an oncology-focused medical technology company. Form 8-K reports cover financial results, business updates, guidance, material events, leadership changes, board composition and Regulation FD disclosures tied to TriNav, PEDD and related oncology development activity.
Proxy materials describe shareholder voting matters, director elections, board committees, executive compensation and equity awards. The filing record also includes capital-structure disclosures for common stock and warrants, material-agreement categories, clinical or regulatory disclosure topics and risk-related information associated with commercializing PEDD infusion systems and developing investigational therapies for solid tumors.
TriSalus Life Sciences CEO Mary T. Szela bought 39,682 shares of common stock in an open-market purchase at a weighted average price of $2.59 per share. After this transaction, she directly holds 1,065,215 common shares.
A footnote explains these purchases are matchable under Section 16(b) against earlier sales that were made solely to cover tax withholding on vesting restricted stock units. The filing states she paid $27,573.70 to the company, equal to the profit from this short-swing transaction.
TriSalus Life Sciences Chief Financial Officer Patience David bought 7,100 shares of the company’s Common Stock in an open-market transaction at $2.43 per share on May 15, 2026. Following this purchase, she directly owns 275,757 Common Stock shares.
TriSalus Life Sciences, Inc. director Gary B. Gordon reported an open-market purchase of company stock. On May 15, 2026, he bought 10,000 shares of Common Stock at $2.46 per share, increasing his direct ownership to 72,510 shares after the transaction.
TriSalus Life Sciences reports a beneficial ownership filing showing 5,374,117 shares held by First Light Asset Management, LLC and Mathew P. Arens, representing 8.75% of the company’s common stock as stated in Item 4.
The filing is a joint Schedule 13G disclosing shared voting and dispositive power of 5,374,117 shares by both the Manager and Mr. Arens; the filing identifies the Manager as investment adviser to accounts and private funds and notes Mr. Arens’ control of the Manager.
TriSalus Life Sciences director Kerry R. Hicks reported new equity awards and updated holdings. Hicks received 28,201 restricted stock units payable in common stock, which fully vest on May 14, 2026, subject to continued service. He was also granted 56,403 director stock options with a $2.52 exercise price, expiring on May 13, 2036, that vest on the same date. Following these grants, Hicks directly holds 542,790 shares of common stock and 145,625 director stock options. Indirect holdings include 1,370,028 shares through HW Investment Partners, LLC, 322,737 shares via The Kerry Raymond Hicks Dynasty Trust, and 81,845 shares held by Millennium Trust Company, LLC, with beneficial ownership in certain entities disclaimed except for his pecuniary interest.
TriSalus Life Sciences director Mats Wahlstrom reported new equity compensation grants. He received 34,226 restricted stock units that vest fully on May 14, 2026, payable in common stock, subject to his continued board service.
He also received a Retainer RSU Award of 37,602 units, taken in lieu of 2026 cash board retainer fees. These RSUs vest in three equal quarterly installments through the remainder of 2026, conditioned on continued service. In addition, he was granted a director stock option for 75,204 shares of common stock at an exercise price of $2.5200 per share, vesting in full on May 14, 2026 and expiring on May 13, 2036.
The filing also shows substantial indirect common stock holdings through Leonard Capital LLC and HW Investment Partners, LLC, where Wahlstrom shares voting and investment discretion, and he disclaims beneficial ownership of HW Investment securities beyond his pecuniary interest.
TriSalus Life Sciences director Gary B. Gordon received equity awards in the form of common stock and stock options. The filing reports grants of 24,553 and 28,201 shares of common stock at a price of $0.00 per share, reflecting restricted stock unit awards.
One RSU award fully vests on the one-year anniversary of the grant date of May 14, 2026, while a separate retainer RSU award vests in three equal quarterly installments through the remainder of 2026, in lieu of cash board fees. In addition, Gordon received a director stock option covering 56,403 shares of common stock at an exercise price of $2.52 per share, expiring in 2036, which also fully vests on the one-year anniversary of the grant date.
TriSalus Life Sciences director David J. Matlin reported equity compensation grants. He received 23,065 restricted stock units that vest in full on the one-year anniversary of the May 14, 2026 grant date, subject to continued service.
He also received 28,201 restricted stock units in lieu of 2026 board service retainer cash fees; these vest in three equal quarterly installments through the remainder of 2026, subject to continued service. In addition, he was granted options to purchase 56,403 shares of common stock at an exercise price of $2.52 per share, vesting in full on the one-year anniversary of the May 14, 2026 grant date. Following these awards, Matlin directly holds 1,323,210 shares of common stock and 121,403 stock options.
TriSalus Life Sciences director William Valle reported equity compensation grants. He received 24,553 restricted stock units and 28,201 additional restricted stock units, both payable in common stock. One award is in lieu of 2026 board retainer cash fees and vests in quarterly one-third installments through 2026.
Valle was also granted a director stock option for 56,403 shares of common stock at an exercise price of $2.52 per share, expiring on May 13, 2036. The RSU awards and option generally vest on the one-year anniversary of the May 14, 2026 grant date, subject to his continued service with the company.
TriSalus Life Sciences director Michael P. Stansky reported new equity awards and updated holdings. He received two grants of restricted stock units covering 20,089 and 23,501 shares of common stock, both payable solely in stock. One RSU award vests fully on the one-year anniversary of the May 14, 2026 grant date, while the retainer RSU award vests in three equal quarterly installments through the remainder of 2026, each subject to his continued board service.
He was also granted a director stock option for 47,003 shares of common stock at an exercise price of $2.52 per share, expiring on May 13, 2036, which will fully vest one year after the grant date if he continues serving. Following these grants, he holds 830,722 common shares directly and 199,698 shares indirectly through Skyview Investments LLC, where he serves as managing member with voting and dispositive power, along with 139,540 director stock options.